List view / Grid view
Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its Evolution 200 series of next-generation UV-Visible spectrophotometers featuring INSIGHT and CUE (Customized User Environment) software has been named one of the most technologically significant products of the past 12 months by R&D Magazine.
19 July 2011 | By The Scott Partnership
Optibrium launches a new version of StarVue...
19 July 2011 | By kdm communications limited
Sigma Life Science, announced the launch of CompoZr Targeted Integration Kit – mRosa26...
19 July 2011 | By Janssen Therapeutics
Janssen Therapeutics, presented 96-week findings from two pivotal Phase 3 clinical trials...
19 July 2011 | By Takeda Pharmaceutical Company Limited
Millennium announced the submission of a supplemental New Drug Application (sNDA) with the U.S. FDA for VELCADE® (bortezomib)...
19 July 2011 | By Eli Lilly and Company
Data presented from the first of two Phase III trials of semagacestat...
19 July 2011 | By Roche
Roche has signed an agreement to acquire 100% of mtm laboratories AG (mtm)...
18 July 2011 | By Eli Lilly and Company
Winner of the 2011 de Leon Prize in Neuroimaging...
18 July 2011 | By Merck
The European Commission approved VICTRELIS™ (boceprevir)...
18 July 2011 | By Eli Lilly and Company
New study results released...
18 July 2011 | By Merck
Extending to nearly five years in previously untreated adults with HIV-1...
15 July 2011 | By Amgen
Amgen announced that the U.S. District Court in Pennsylvania has entered final judgment and a permanent injunction against TEVA...
15 July 2011 | By Amgen
The European Commission has granted marketing authorization for XGEVA® (denosumab)...
15 July 2011 | By Abbott
Abbott plans to develop two new formulations of its HIV medicines...
15 July 2011 | By Novartis
Novartis announced that the Company has started shipping seasonal influenza vaccine to its US customers for the 2011-2012 influenza season...
